Claude Labrie

Affiliations: 
Universite Laval (Canada) 
Area:
Molecular Biology, Oncology, Cell Biology
Google:
"Claude Labrie"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Labrie F, Archer DF, Bouchard C, et al. (2015) Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas. 81: 46-56
Archer DF, Labrie F, Bouchard C, et al. (2015) Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.)
Bouchard C, Labrie F, Archer DF, et al. (2015) Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. Climacteric : the Journal of the International Menopause Society. 18: 590-607
Labrie F, Archer D, Bouchard C, et al. (2014) Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. The Journal of Sexual Medicine. 11: 1766-85
Choi J, Djebbar S, Fournier A, et al. (2014) The co-chaperone DNAJC12 binds to Hsc70 and is upregulated by endoplasmic reticulum stress. Cell Stress & Chaperones. 19: 439-46
Labrie F, Martel C, Bérubé R, et al. (2013) Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. The Journal of Steroid Biochemistry and Molecular Biology. 138: 359-67
Labrie F, Archer DF, Bouchard C, et al. (2011) Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric : the Journal of the International Menopause Society. 14: 282-8
Labrie F, Archer D, Bouchard C, et al. (2010) High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology. 26: 524-32
Labrie F, Archer D, Bouchard C, et al. (2009) Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause (New York, N.Y.). 16: 897-906
Labrie F, Archer D, Bouchard C, et al. (2009) Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause (New York, N.Y.). 16: 907-22
See more...